

# (12) UK Patent Application (19) GB (11) 2 177 096A

(43) Date of printing by UK Office 14 Jan 1987

(21) Application No 8608827

(22) Date of filing 3 Sep 1985

(30) Priority data

(31) 8422238 (32) 2 Sep 1984 (33) GB

(86) International application data  
PCT/GB85/00392 En 3 Sep 1985

(87) International publication data  
WO86/01533 En 13 Mar 1986

(71) Applicant  
Celltech Limited

(Incorporated in United Kingdom),

244—250 Bath Road, Slough, Berkshire SL1 4DY

(72) Inventors  
Michael Samuel Neuberger,  
Terence Howard Rabbitts

(51) INT CL<sup>4</sup> (as given by ISA)

C12N 15/00 A61K 39/395 C07K 3/18 15/00 C12N 5/00  
C12P 21/00 G01N 33/563

(52) Domestic classification (Edition I)

C3H 431 642 656 675 690 B7M  
C6Y 404 501 503  
U1S 2419 C3H

(56) Documents cited by ISA

EP A	0150126	EP A	0090898
EP A	0125023	EP A	0068763
EP A	0120694	WO A	83/03971
EP A	0105521	WO A	84/00382

Chemical Abstracts, volume 95, no. 4, 27 July 1981,  
page 363, abstract 30711m

Nature, 314 no. 6010, April 1985, pages 452-454

Nature, 314, no. 6008, 21 March 1985, pages 268-270

Nature 312, no. 5995, December 1984, pages 643-646

Nature 312, no. 5995, December 1984, pages 604-608

(58) Field of search by ISA


IPC<sup>4</sup> C12N; C12P

(74) Agent and/or Address for Service

Carpmaels & Ransford, 43 Bloomsbury Square, London  
WC1A 2RA.

## (54) Production of chimeric antibodies

(57) A process for the production of a chimeric antibody, comprising: a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first path which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein: b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule; c) transforming an immortalised mammalian cell line with the or both prepared vectors; and d) culturing said transformed cell line to produce the chimeric antibody; chimeric antibodies produced by this process; and plasmids and transformed cell lines used in the process.



GB 2 177 096 A